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Abstract
Background: International guidelines for the surveillance of breast cancer patients recommend a minimized clinical follow-
up including routine history and physical examination and regularly scheduled mammograms. However, the abandonment 
of scheduled follow-up examinations in breast cancer survivors remains a contradiction to established follow-up guidelines 
for other solid tumours.
Patients and Methods: We report the patients’ view on the basis of a survey performed in two separate geographical areas 
in Germany. The questionnaires were sent out to 2.658 patients with a history of breast cancer.
Results: A total of 801 patients (30.1%) responded to the questionnaire. The results of the survey can be summarized in 
two major categories: First, necessity for surveillance was afﬁ  rmed by a majority (95%), and 47.8% of the organized 
patients answered that there was a need for more intensive diagnostic effort during follow-up. The main expectation from 
an intensiﬁ  ed follow-up was the increased feeling of security as expressed by 80% of the women. Second, the present 
survey indicates that most of the regularly scheduled follow-up visits were expanded using extensive laboratory and imag-
ing procedures exceeding the quantity of examinations recommended in the present follow-up guidelines.
Conclusion: Despite the fact that only one third of the patients responded to the questionnaire, the survey indicates that a 
majority of physicians who treated these patients still do not accept the present follow-up guidelines. To some extent this 
may be explained by the observation that patients and possibly also their doctors trust that intensiﬁ  ed follow-up increases 
diagnostic security and survival. Since considerable changes in the treatment options of breast cancer have been made dur-
ing the last decades a new trial of investigations in follow-up is warranted.
Keywords: breast cancer, follow-up, guidelines, surveillance
Introduction
The care of patients who survived their breast cancer requires an understanding of patterns of relapse as 
well as the unique medical and psychological needs that arise in this group of patients. One primary goal 
of surveillance is the early recognition and treatment of potentially curable disease recurrence. A major-
ity of breast cancer recurrences occur during the ﬁ  rst decade after primary therapy, particularly during 
years 2 to 5; however, they can occur much later [1–4]. A recent meta-analyses of 12 studies involving 
5.045 patients found that 40% of patients with loco-regional recurrences were diagnosed during routine 
clinic visits, whereas the remainder (60%) developed symptomatic recurrences between the intervals of 
regularly scheduled clinical visits [5]. Recommendations regarding surveillance for disease relapse are 
based upon guidelines issued in an update 2006 from the American Society of Clinical Oncology (ASCO) 
[6]. These guidelines included routine history and physical examination and regularly scheduled mam-
mograms and excluded intensiﬁ  ed laboratory and imaging procedures for asymptomatic patients [6].18
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It has often been discussed if an intensiﬁ  ed fol-
low-up, expanded by intensive laboratory and 
imaging procedures improves the outcome of 
breast cancer patients and survivors. Two rand-
omized trials and a Cochrance review have con-
cluded that there is no survival beneﬁ  t from more 
intensive surveillance during post-treatment fol-
low-up [7–10]. Moreover, no study exists, which 
has evaluated the beneﬁ  t of more frequent clinical 
visits in patients with known high-risk versus low-
risk disease [6]. Finally, a follow-up that was not 
guideline-compliant costs 2.2 to 3.6 times more 
than a guideline-compliant follow-up [11, 12].
However, the abandonment of scheduled 
follow-up examinations in breast cancer patients 
and survivors remains a contradiction to estab-
lished follow-up guidelines for other solid tumours. 
Taking into consideration that treatment options 
for breast cancer have improved continuously over 
the last years, it is mandatory to initiate a new 
surveillance study which investigates the inﬂ  uence 
of these improved possibilities on survival.
The present survey was performed to analyze 
the reality in the existential orientation of women 
with breast cancer in the phase of follow-up and 
to evaluate the patients’ view on the issue of sur-
veillance after breast cancer in preparation for a 
new surveillance study.
Patients and Methods
Patient recruitment
The present analysis based on a patient survey 
initiated in two different states (Nordrhein-
Westfalen and Bavaria) of Germany in the year 
2005. A questionnaire was sent out to 2.658 
patients with a history of breast cancer.
The selection of patients based on the databases 
of a self-help organization (Mamazone e.V., 
Augsburg, Germany) and a local health insurance 
company (AOK Rheinland/Hamburg, Germany).
Due to the completely anonymous questionnaire 
an approval by an ethics committee was not man-
datory. There was no designated recall for non-
responders. Among 801 patients who responded 
to the questionnaire, 476 (59.4%) were organized 
in a self-help group.
The questionnaire
The questionnaire was developed in a cooperative 
effort of medical oncologists, gynaecologists 
and the German breast-cancer advocacy-group 
mamazone. The questionnaire included 29 questions 
with 58 variables and is accessible on the homepage 
of our department (http://med3.klinikum.
uni-muenchen.de/ycms/Studien_80.htm).
Statistical methods
The data of the survey were analyzed with descrip-
tive statistical methods. Differences between 
patient groups were analyzed using the χ²-test 
(Chi-square test).
Results
Baseline characteristics
From 2.658 patients who were included in the survey 
a total of 801 patients replied to the questionnaire 
(30.1%). The median age amounts to 62 years 
(range 23–85 years). More than half of the 
respondents were members of a self-help organiza-
tion (59.4%).
The majority of the patients were disease-free 
at the time of the survey (71.7%). Loco-regional 
recurrence was diagnosed in 13.4% and the remain-
ing 14.9% had metastatic disease at the time of the 
survey.
Follow-up: The patients’ view
Independent of a membership to a self-help orga-
nization a majority of the patients afﬁ  rmed the need 
for follow-up after primary treatment of breast 
cancer. Necessity of surveillance was afﬁ  rmed by 
95.3% of the members of a self-help group which 
was comparable to 96.3% in non-organized patients 
(Fig. 1).
When asked for the adequacy of the present 
follow-up, nearly one-half of the organized 
patients (47.8%) and one-third of the non-
organized patients (32.9%) asked for more 
laboratory and imaging procedures during their 
follow-up exams. About two third of the non-
organized and the half of the organized patients 
accepted the present intensity of follow up (self-
help group vs non-organized patients, 51.3 vs 
64.5%; Fig. 2).
In view of the unsatisfactory evidence of clinical 
studies on follow-up in breast cancer the present 
survey includes the question if the afﬂ  icted women 
are willing to participate in a clinical study on 
follow-up. Only about a quarter of the patients 19
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Figure 1. Question: Necessity of surveillance?
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Figure 2. Question: Adequacy of the present surveillance regimen?
(self-help group vs non-organized patients, 25.4 vs 
27.1%) indicated that they would participate in a 
trial randomising between conventional and more 
intensive follow-up, whereas the majority would 
prefer participation in a single-arm, non-randomized 
trial including an intensiﬁ  ed follow-up (self-help 
group vs non-organized patients, 58.8 vs 43.4%) 
(Fig. 3).
Independent of the membership to a self-help 
organization, more than 80% of the responders stated 
that regularly scheduled visits during follow-up are 
important to come to terms with the disease.20
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Figure 3. Question: Willing to participate in a surveillance study?
When asked for the consequences following 
from a more intensiﬁ  ed follow-up, more than 80% 
of the patients stated that intensiﬁ  cation of follow-up 
was associated with an increased sense of security 
(Fig. 4). And independent of the membership to a 
self-help organization, a majority of the patients in 
the surveys believed that earlier detection of any 
recurrence or metastatic spread will improve sur-
vival (97%, e.g. 95.8% of the organized patients).
When asked for the attitude to life a quarter of 
the organized (25%) and a third of the non-
organized (33%) patients responded that they 
would prefer to neglect rather than to constantly 
analyze the disease. Moreover, about a third of the 
respondents stated that they feel conﬁ  dent and 
comfortable and the disease has been overcome 
(34%, e.g. 28% of the organized patients).
Disease status and patients’ view
283 patients (35.3%) experienced loco-regional 
recurrence or metastatic disease during follow-up. 
Necessity for surveillance was afﬁ  rmed by 98.3% 
of the responders. The overwhelming majority (90%) 
of these patients required more laboratory and imag-
ing procedures during their follow-up exams.
Follow-up—reality
When asked for the regularly scheduled follow-up 
visits in the past, it was obvious, that most of those 
visits were expanded with extensive laboratory tests 
and imaging procedures. Those procedures were 
offered signiﬁ  cantly more often to patients who 
were organized members of a self-help group. A 
signiﬁ  cant difference was determined for routine 
history, laboratory testing including tumor marker 
tests, and imaging procedures except CT or PET-CT 
scans, which were all performed more frequently 
in patients who were organized members of a self-
help group (Table 1). It is noteworthy that the 
questionnaire asked for tests routinely offered to 
the patients regardless to the presence of clinical 
symptoms of loco regional recurrent or metastatic 
disease.
Discussion
Nearly all national and international guidelines for 
follow-up of breast cancer patients do explicitly 
not recommend regular laboratory and imaging 
screening procedures for asymptomatic patients. 
According to these guidelines, follow-up should 
be focussed on the breast. Only patients with sus-
pected tumour-related symptoms should be 
screened for metastatic spread. The American 
Society of Clinical Oncology 2006 update of the 
breast cancer follow-up and management guide-
lines in the adjuvant setting concluded, that careful 
history, physical examination and regular mam-
mography performed by an experienced physician 21
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Figure 4. Question: Intensiﬁ  cation of surveillance leads to…?  
are appropriate for detection of breast cancer 
recurrence in asymptomatic patients [6].
Although an intensiﬁ  ed follow-up may detect 
asymptomatic disease recurrence, two randomized 
trials and a Cochrane analysis failed to demonstrate 
a survival beneﬁ  t from more intensive surveillance 
during post-treatment follow-up [7–10]. However, 
diagnostic tools and treatment options have 
improved continuously over the last years. Despite 
the fact that both trials in the 80’s were powered 
to draw the conclusions they made, some minor 
but also major concerns remained:
Table 1. Question: Routine surveillance tests performed during follow-up (n = 801).
  Self-help group   Non-organized  p
 (n  = 476) [%]   (n = 325) [%]  [χ²-test]
• Clinical tests  
 Physical  examination  88.2  85.5  ns  (p  = 0.26)
 Routine  history  97.9  92.9  p  = 0.005
• Laboratory tests    
 Laboratory  tests  90.8  82.5  p  = 0.005
 Tumour  marker  tests  86.9  56.0  p   0.0005
• Imaging procedures    
 Chest  x-ray  66.0  52.0  p   0.0005
 Ultrasound  92.2  85.5  p  = 0.002
 Bone  scan  61.1  35.7  p   0.0005
  Computed tomography  35.7  29.5  ns (p = 0.07)
  PET-CT scan  9.0  12.0  ns (p = 0.17)
 Mammography  94.3  89.2  p  = 0.008
ns: not signiﬁ  cant22
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Minor concerns
•  Both studies are of limited value for patients 
with a higher risk of relapse since more than 
50% of the included patients were node-negative 
and only a minority (10%) of the patients had 
larger tumours (pT3 and pT4) [9, 10].
•  Only one trial included regularly scheduled 
ultrasound studies of the liver at yearly inter-
vals! Laboratory tests did not include tumour 
marker analyses [10].
•  It is critical to consider that in both studies the 
relapse rate amounts to 20% at 5 years which 
is clearly in contrast to a higher relapse rate 
(relapse rate at 5 years up to 40%) as reported 
in other studies [13].
Major concerns
•  Considerable changes in surgical procedures, 
innovations in interventional radiology and an 
improvement in the systemic treatment options 
of breast cancer have been made in the last dec-
ades, which were all not considered in those 
trials [14–17]. For example, it has been demon-
strated that an aggressive surgical approach 
improves the outcome of highly selected patients 
with oligometastatic breast cancer [17].
This non-representative investigation was initi-
ated to evaluate two major issues: First to reﬂ  ect 
the reality of follow-up as performed typically in 
women with a history of breast cancer and second, 
to evaluate the patients’ view. The results of this 
can be summarized in two major categories:
As demonstrated in Table 1, a majority of the 
physicians who treated these patients obviously 
does not accept the present follow-up guidelines. 
To some extent this may be explained by the obser-
vation that patients and possibly also their doctors 
trust that intensiﬁ  ed follow-up increases diagnos-
tic security. Unsurprisingly, those extensive labo-
ratory tests and imaging procedures were offered 
signiﬁ  cantly more often to patients who were 
organized members of a self-help group. This is 
partly explained by better informed patients who 
insist upon an intensiﬁ  ed follow-up (Table 1).
Independent of the membership to a self-help 
organization, the overwhelming majority of the 
patients who responded to the questionnaire 
affirmed the general necessity for follow-up 
(95%) and 47.8% of the organized patients 
answered that there was a need for more intensive 
diagnostic effort with regard to laboratory exams 
and imaging procedures during follow-up (32.9% 
of non-organized patients). Unsurprisingly, this 
percentage was much higher in patients with recur-
rent or metastatic disease (90%). Contrary to com-
mon belief more than 80% of the respondents 
stated that this intensiﬁ  cation of follow-up was not 
associated with an increased sense of uncertainty 
but rather an increased sense of security. This has 
been consistently found in a Dutch study of de 
Bock et al. [18]. Nevertheless, it is critical to dis-
cuss that these data are in contrast to those of 
Gulliford et al. [19]. In their study patients were 
randomly assigned to a conventional schedule of 
clinic visits or to a reduced schedule of clinic vis-
its only after mammography. Twice as many 
patients in both groups expressed a preference for 
reducing rather than increasing follow up [19]. 
Moreover, Geller et al. found in an analysis of 
seven mammography registries that despite recom-
mendations by professional organizations, many 
women have not returned for mammography after 
treatment for breast cancer [20]. Taking into con-
sideration that a majority afﬁ  rmed the general 
necessity of surveillance for breast cancer in the 
conducted surveys, a quarter of the organized 
(25%) and a third of the non-organized (33%) 
patients responded contrary, that they prefer to 
neglect the disease. Moreover, about a third of the 
respondents stated that they feel conﬁ  dent and that 
the disease has been overcome (34%, e.g. 28% of 
the organized patients).
A major limitation of this investigation is due to 
the fact that only one third of the patients responded 
to the questionnaire. It is critical to discuss that prob-
ably those patients responded who are engaged in 
the topic of follow-up. The absence of a designated 
recall for non-responders therefore remains an open 
point of discussion. Furthermore, a majority of the 
patients who returned the questionnaire were organ-
ized members of a self-help group which potentially 
explains the extensive technical effort performed in 
those patients during follow-up. Despite these limi-
tations, the present data reﬂ  ect the ethical struggle 
of the physicians as well as the wishes of the afﬂ  icted 
patients and are therefore providing a solid basis for 
a new surveillance study.
Conclusion
In summary one can conclude that women with 
a history of breast cancer have conﬂ  icting views 23
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on follow-up. Moreover clinicians obviously do 
not agree with the conclusions of older studies on 
which present guidelines are based. Lacking new 
evidence it is about time to initiate a new rand-
omized surveillance study which investigates the 
efﬁ  cacy of an intensiﬁ  ed surveillance based on 
the improved possibilities of modern diagnostics 
and endocrine, immunotargeted, chemotherapeu-
tical and interventional treatment options. Not 
only the physicians, but specifically also the 
women with breast cancer are prepared and deter-
mined to reanalyse this important ﬁ  eld of onco-
logical activity.
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